Fatal hemolytic uremic syndrome associated with day care surgery and anaesthesia: a case report by unknown
Myrnäs and Castegren BMC Research Notes 2013, 6:242
http://www.biomedcentral.com/1756-0500/6/242CASE REPORT Open AccessFatal hemolytic uremic syndrome associated with
day care surgery and anaesthesia: a case report
Anna Myrnäs1 and Markus Castegren2,3*Abstract
Background: Thrombotic angiopathies, i.e. haemolytic uremic syndrome and thrombotic thrombocytopenic
purpura, are thought to occur in patients with a combination of risk factors (e.g., an infection with shiga-toxin
-producing Escherichia coli (E. coli) or low activity of the metalloproteinase Adamts-13) and a pathophysiological
trigger (e.g., anti-endothelial antibodies, cytokines or activation of chemokine receptor 4). To our knowledge, this is
the first report describing an association between haemolytic uremic syndrome and routine surgery and
anaesthesia.
Case presentation: We present a case in which a 67-year-old Caucasian female developed fatal haemolytic uremic
syndrome in the immediate postoperative period of uncomplicated day care surgery. The patient had suffered
gastrointestinal symptoms followed by confusion approximately two weeks before surgery, but had been without
any symptoms in the week before surgery. Haemolytic uremic syndrome with cerebral symptoms ranging from
initial anxiety to subsequent seizures and coma developed within a few hours after the end of surgery. In addition,
acute kidney failure and severe thrombocytopenia occurred about the same time. During intensive care, the patient
was found to be positive for enterohaemorrhagic E. coli (EHEC) in faeces.
Conclusion: Anaesthesiologists should be notified that haemolytic uremic syndrome is an uncommon differential
diagnosis in patients with postoperative seizures and coma. Patients with a recent enterohemmoragic E.Coli
infection should be followed postoperatively for signs of haemolytic uremic syndrome.
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General anaesthesiaBackground
Haemolytic uremic syndrome (HUS) is characterised by
three prominent attributes: haemolytic anaemia, acute
kidney failure and thrombocytopenia [1]. The most com-
mon cause of classical HUS (STEC-HUS) is infection
with shiga-toxin-producing Escherichia coli (E. coli)
0157:H7. Typically, the incubation period is 3–5 days
and approximately 5-15% of infected patients develop
HUS. Children are more often affected than adults.
Neurological involvement is uncommon [2]. During the
German major outbreak of HUS in 2011, patients were
infected with E. coli O104:H4. During the outbreak, over* Correspondence: markus.castegren@dll.se
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distribution, and reproduction in any medium20% of the infected patients developed HUS and 88% of
the cases with HUS occurred in adults. Particularly note-
worthy was that 68% of the patients were women [3].
Furthermore, neurological involvement was common,
whereas the incidence of bloody diarrhoea was infre-
quent [4]. Neurological symptoms occurred at the same
time as there was an increase of lactate dehydrogenase
and creatinine and the nadir of the platelet count oc-
curred before the onset of neurological symptoms [5].
The patients needed mechanical ventilation for an ave-
rage of five days and started to be seizure free after an
average of three days [5].
In patients in whom no infection with shiga-toxin-pro-
ducing E. coli is found, i.e. atypical HUS (aHUS), muta-
tions in genes encoding proteins of the alternative
pathway of the complement system have been identified
[6]. A third condition very similar in presentation and
pathophysiology, thrombotic thrombocytopenic purpurad Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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metalloproteinase Adamts-13 or antibodies to the pro-
tein [7]. All three conditions are sometimes referred to
as thrombotic microangiopathies (TMAs) [7].
In contrast to aHUS, which has a known risk of recur-
rence following renal transplantation [8], STEC-HUS is
regarded as a unique event not associated with recur-
rence of the symptoms [9]. In the reports after the 2011
outbreak of STEC-HUS no comments about patients
with recurrent presentations were noted [5,10].
Drug-associated HUS is a commonly acknowledged
condition in which the proposed mechanisms are direct
endothelial effects or immune-mediated effects associ-
ated with deficient Adamts-13 activity [11]. The most
commonly implicated drugs are quinine, mitomycin-C,
tacrolimus and cyclosporine, as well as platelet-acting
drugs, such as clopidogrel and ticlopidine [12]. Other
than the most common drugs associated with HUS,
reports of a suspected association can be found be-
tween the development of HUS and treatment with
antibiotics, i.e. penicillin and piperacillin, non-steroidal
anti-inflammatory drugs, H2-receptor antagonists and
simvastatin [11].
Adamts-13 protein deficiency is not enough for the
development of TTP; rather, a pathophysiological trigger
is required for the precipitation of the condition [13].
Anti-endothelial antibodies or cytokines have been pro-
posed as such triggers [13]. An interplay between a
predisposing condition and a pathophysiological trigger
is most likely also required in STEC-HUS and aHUS,
where activation of chemokine receptor 4 (CXCR4/
stromal cell-derived factor-1(SDF-1) pathway) has been
proposed as a trigger mechanism [14]. Ubiquitin, a na-
tural CXCR4 agonist [15], is released systemically fol-
lowing trauma and inflammation [16].
Evidenced-based treatments for TMAs are lacking;
however, plasma exchange therapy has been used with
varying success [17]. Complement inhibitor treatment
with the monoclonal antibody against the complimentTable 1 Development of the glasgow coma scale and laborat
Days after surgery Pre-operative
analyses
Glasgow coma scale 15
Haemoglobin (g × L-1) 121
Platelet count (109 × L-1)
Leukocyte count (109 × L-1)
C-reactive protein (μmol × L-1)
Creatinine (μmol × L-1) 53
Prothrombin time (INR)
Bilirubin total (μmol × L-1)
Lactate dehydrogenase (μkat × L-1)protein C5, eculizumab, has been used successfully in re-
cent trials in aHUS [6].
To our knowledge, there are no publications or case
reports describing an association between STEC-HUS
with uncomplicated anaesthesia and routine orthopaedic
surgery.
Case presentation
A 67-year-old Caucasian female with glipizide- and met-
formin-treated diabetes mellitus and enalapril-treated ar-
terial hypertension presented for open reposition and
Zuggurtung fixation of a fracture of the olecranon. The
elbow was fractured in a bicycle accident and had been
conservatively treated for 14 days prior to surgery. The
patient had suffered from diarrhoea and signs of confu-
sion in the period between the trauma and surgery, but
had been free of gastrointestinal or neurological symp-
toms during the week before surgery. The patient had
not sought professional medical advice for these symp-
toms. When the patient presented for surgery, she was
lucid, without any gastrointestinal symptoms and other-
wise physically well. The preoperative laboratory work-
up tests were without pathological signs (Table 1). At
the operating ward, 1 g paracetamol, 100 mg diclofenac,
10 mg oxycodone and 25 mg meclizine were admi-
nistered orally as premedication. The anaesthesia was
induced with propofol and fentanyl. The airway was se-
cured by orotracheal intubation after which the anaes-
thesia was maintained with sevoflurane. The time of
surgery was 31 min and the total anaesthesia duration
was 70 min. After uncomplicated surgery and anaesthe-
sia, the patient was transferred to the postoperative unit
from where the patient went home after 3 h accompan-
ied by her next of kin. During the first postoperative
evening and night, the patient’s next of kin observed that
the patient had problems with articulating words fol-
lowed by increasing anxiety and confusion. At the next
morning, the patient only spoke unrecognizable words,
and by the afternoon, she could not walk. Approximatelyory parameters
1 2 4 6 13
11 3 6
111 86 101 102 104
112 31 84 113 389
8.6 9.3 11 12.1 28.5
76 134 59 9 30
207 313 209 128
1.1 1.1 1.1 1.1 1.1
24 7
21.5 4
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the emergency ward. Respiration and circulation were
normal and the patient was afebrile. A computed tomog-
raphy (CT) scan of the brain was performed as well as
an analysis of the cerebrospinal fluid, with both indicat-
ing no pathological signs. A neurological consult ordered
an electroencephalogram (EEG) and a magnetic reson-
ance imaging (MRI) of the brain to be performed as
soon as possible at a secondary hospital to which the pa-
tient was referred. At arrival to the secondary hospital
on the second postoperative day, the patient did not re-
spond verbally, could not open her eyes spontaneously
and the best motor response was withdrawal of the
limbs on pain stimulation (Glasgow Coma Scale, GCS 9).
It was noted that plasma creatinine was elevated to
313 μmol × L-1. Except for an elevated C-reactive protein
(CRP) at 76 mg × L-1, all blood analyses were in the nor-
mal range, including haemoglobin, leucocyte and platelet
count. On the night between the second and third postop-
erative day, the patient suffered a generalised tonic-clonic
seizure. The patient was transferred to the intensive care
unit, where she, was orotracheally intubated and mechan-
ically ventilated. A second CT scan of the brain showed
no bleeding or ischaemic signs. The patient was respira-
tory and circulatory stable and did not require an in-
creased oxygen fraction or vasoactive drugs. The patient
was anuric, was not icteric and did not have any patho-
logical signs on the skin. Blood cultures were drawn and
an antibiotic was given based on a body temperature of
38.9°C and tachycardia. The patient was started at 4 g
piperacillin-tazobactam 3 times per day intravenously
(i.v.). The cultures did not show any bacterial growth. Be-
cause the patient had elevated serum potassium of
5.8 mmol × L-1 and hyponatraemia of 131 mmol × L-1,
blood was analysed for serum cortisol on the suspicion
of Addison’s disease. Accordingly, the patient was given
100 mg hydrocortisone i.v. Cortisol in serum was found to
be 796 nmol × L-1 and thus the suspicion of Addison’s dis-
ease was refuted. The patient was now anaemic with a
haemoglobin of 86 g × L-1 and thrombocytopenic with a
platelet count of 31 × 109 × L-1. Lactate dehydrogenase
was elevated to 21.5μkat × L-1 and haptoglobin low at
0.07 g × L-1, which indicate haemolysis. The blood film
showed schistocytosis., On the third postoperative day,
plasmapheresis was started on the indication of HUS/
TTP. One plasma volume was replaced daily for four
days and continuous veno-venous haemodiafiltration was
performed between plasmapheresis treatments. The pa-
tient’s haemoglobin and platelet count improved during
treatment (Table 1). The same positive development was
seen for creatinine. Neurological status improved slowly
and on the seventh postoperative day, GCS was 6 with
withdrawal of the limbs on pain stimulation. Polymerase
chain reaction (PCR) revealed enterohaemorrhagic E. coli(EHEC) in faeces. The serotype was non-O157, produced
verotoxin type 2 and was eae-gene negative. Blood analysis
of Adamts-13 protein activity showed normal levels and
antibodies against the protein were not observed. Signs of
multiple small ischaemic fronto-temporal cortical lesions
were noted on an MRI scan, as well as lesions in the
circulus Willisi and the basilar artery with narrowing and
more distal dilatations of the vessels. Analyses of anti-
neutrophil antibodies and anti-neutrophil cytoplasmic
antibodies were negative. The neurological consult as-
sessed the clinical picture together with the MRI findings
as thrombotic microangiopathy. The patient continued to
show slow improvement in neurological status with spon-
taneous eye opening and the ability to move all limbs, al-
though with substantial weakness. The patient could make
eye contact on instructions on the 20th postoperative day
but was still anuric and in need of intermittent haemo-
dialysis and mechanical ventilatory support. On the 21st
postoperative day, the patient suffered a generalised tonic-
clonic seizure followed by deep coma (GCS 3). EEG
showed generalised deeply suppressed activity. A joint
decision was made with the next of kin to withdraw
all treatment. The patient died 6 h later.
Discussion
The present case of a patient with gastrointestinal
symptoms before the onset of HUS and positive PCR of
EHEC in faeces is a classic case of HUS. The features of
the E. coli being non-serotype O157, verotoxin 2-produ-
cing and eae-gene negative, together with the neuro-
logical symptoms in an adult female, are uncharacteristic
of classical STEC-HUS but similar to the German out-
break of E. coli O104:H4 in 2011 [4]. In this case, the pa-
tient had suffered gastrointestinal symptoms followed
with transient confusion and recovered from all symp-
toms over a week prior to surgery. However, in the im-
mediate postoperative period, the cerebral symptoms
recurred, only now with rapid deterioration from con-
fusion and agitation to fulminant epileptic seizures and
deep coma. The progression from a patient without
symptoms before surgery and anaesthesia to fulminant
HUS in conjunction with deep unconsciousness took
less than 48 h. This close temporal relationship suggests
a direct causal effect between the therapy given during
surgery and anaesthesia and the recurrence of fulminant
HUS. It might be hypothesised that the inflammatory re-
sponse induced by surgery and anaesthesia activated cell
surface receptors (e.g., CXCR4) in a patient at risk of de-
veloping HUS because of an EHEC infection, which
would hasten the progression of the disease [13-16]. The
noteworthy association in time between anaesthesia for
uncomplicated surgery and the unique recurrence of
STEC-HUS has, to our knowledge, not been described
previously.
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Anaesthetists and surgeons should be notified of HUS/
TTP as an uncommon differential diagnosis of seizures
and coma in the postoperative period. Patients with a re-
cent EHEC infection should be followed postoperatively
for signs of HUS.
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